Viewing Study NCT06479135

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 10:13 PM

Ignite Modification Date: 2026-04-11 @ 12:40 PM

Study NCT ID: NCT06479135

Status: RECRUITING

Last Update Posted: 2025-09-25

First Post: 2024-06-21

Is NOT Gene Therapy: True

Has Adverse Events: False

Brief Title: Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Sponsor: Kartos Therapeutics, Inc.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module